Search

Displaying results 3801 - 3810 of 5897 in total
  1. Drug

    Etrolizumab

    go.drugbank.com/drugs/DB12189
    Investigational

    [A244564, A244569, A244579, A244584] A recent class of drugs designed to impair lymphocyte homing, so-called "anti-trafficking agents" (ATAs), have shown some success and include approved drugs such as … [A244564, A244584] Etrolizumab is a humanized IgG1κ monoclonal antibody directed against the β7 subunit of gastrointestinal α4β7 and αEβ7 integrins that, due to its target specificity, appears as or more

  2. Drug

    Nafamostat

    go.drugbank.com/drugs/DB12598
    Investigational

    Nafamostat is a synthetic serine protease inhibitor that is commonly formulated with hydrochloric acid due to its basic properties. … The use of nafamostat in Asian countries is approved as an anticoagulant therapy for patients undergoing continuous renal replacement therapy due to acute kidney injury.

  3. Drug

    Dazodalibep

    go.drugbank.com/drugs/DB19025
    Investigational

    Dazodalibep is under investigation in clinical trial NCT06104124 (A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic

  4. Drug

    Pemrametostat

    go.drugbank.com/drugs/DB19170
    Investigational

    Pemrametostat is under investigation in clinical trial NCT03614728 (Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute

  5. Drug

    IMVT-1402

    go.drugbank.com/drugs/DB21979
    Investigational

    IMVT-1402 is under investigation in clinical trial NCT06754462 (A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid

  6. Drug

    Givosiran

    go.drugbank.com/drugs/DB15066
    Approved

    first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic disorder in which the overproduction of toxic heme intermediates leads to

  7. Drug

    Anivamersen

    go.drugbank.com/drugs/DB16089
    Investigational

    Anivamersen is under investigation in clinical trial NCT01848106 (A Study to Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI).

  8. Drug

    Ramosetron

    go.drugbank.com/drugs/DB09290
    Investigational

    Ramosetron is a _serotonin 5-HT3 receptor antagonist_ commonly employed to treat nausea and vomiting, in addition to certain diarrheal conditions. … It is believed to have higher potency and longer antiemetic action than other 1st generation 5-HT3 antagonists such as ondansetron.

  9. Drug

    1-(3-bromophenyl)-7-chloro-6-methoxy-3,4-dihydroisoquinoline

    go.drugbank.com/drugs/DB08555
    Experimental

    This compound belongs to the isoquinolines and derivatives. … This medication is known to target mitogen-activated protein kinase 10.

  10. Drug

    (1H-indol-3-yl)-(2-mercapto-ethoxyimino)-acetic acid

    go.drugbank.com/drugs/DB03455
    Experimental

    This compound belongs to the indole-3-acetic acid derivatives. … These are compounds containing an acetic acid (or a derivative) linked to the C3 carbon atom of an indole. (1H-indol-3-yl)-(2-mercapto-ethoxyimino)-acetic acid is known to target interleukin-2.